Suppr超能文献

乳腺导管内癌的根治性放疗。

Definitive irradiation for intraductal carcinoma of the breast.

作者信息

Solin L J, Fowble B L, Schultz D J, Yeh I T, Kowalyshyn M J, Goodman R L

机构信息

Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia.

出版信息

Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):843-50. doi: 10.1016/0360-3016(90)90003-3.

Abstract

During the period from 1978 to 1985, 51 women with intraductal carcinoma of the breast were treated with definitive irradiation following breast-conserving surgery. Surgical treatment of the primary tumor in all patients consisted of excisional biopsy or wide resection. In general, definitive irradiation consisted of conventional breast tangents to 4500-5000 cGy followed by a breast boost to a total dose of 6000-6600 cGy (median = 6000 cGy; range = 4200-6600 cGy). No patient was treated with radiation to a supraclavicular or axillary field. For the 51 patients, the median follow-up was 68 months (range = 25-126 months). The 5-year actuarial rate of local failure was 6%. A total of five patients failed in the breast at 19, 35, 40, 79, and 119 months following definitive irradiation. Salvage treatment in these five patients consisted of mastectomy in all five patients plus adjuvant tamoxifen in one patient. All five of the patients with breast failures are alive and NED (no evidence of disease), although with limited follow-up (median = 12 months; range = 6-68 months). These results suggest that definitive irradiation is an acceptable alternative to conventional mastectomy for appropriately selected and staged patients with intraductal carcinoma of the breast. In view of the long natural history of this disease, prolonged and careful follow-up of these patients is required.

摘要

1978年至1985年期间,51例乳腺导管内癌患者在保乳手术后接受了根治性放疗。所有患者原发肿瘤的手术治疗包括切除活检或广泛切除。一般来说,根治性放疗包括常规乳腺切线野照射至4500 - 5000 cGy,随后乳腺加量照射至总剂量6000 - 6600 cGy(中位数 = 6000 cGy;范围 = 4200 - 6600 cGy)。没有患者接受锁骨上或腋窝野放疗。51例患者的中位随访时间为68个月(范围 = 25 - 126个月)。5年局部复发的精算率为6%。共有5例患者在根治性放疗后19、35、40、79和119个月出现乳腺复发。这5例患者的挽救性治疗包括全部5例均行乳房切除术,其中1例加用辅助性他莫昔芬。所有5例乳腺复发患者均存活且无疾病证据(NED),尽管随访时间有限(中位数 = 12个月;范围 = 6 - 68个月)。这些结果表明,对于经过适当选择和分期的乳腺导管内癌患者,根治性放疗是传统乳房切除术的可接受替代方案。鉴于该疾病的自然病程较长,需要对这些患者进行长期且仔细的随访。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验